SAG
SPRO icon

SageView Advisory Group’s Spero Therapeutics SPRO Stock Holding History

SageView Advisory Group’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$40 Buy
+17
New +$39 ﹤0.01% 2572

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

SageView Advisory Group's SPRO Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Spero Therapeutics (SPRO) in Q4 2025: 17 shares worth $40. The stake represents ﹤0.01% of the portfolio and ranks #2572 among its holdings.

56 funds tracked by Wall St. Rank hold SPRO as of Q4 2025.

  • SageView Advisory Group held 17 shares of Spero Therapeutics worth $40 as of Q4 2025.
  • Spero Therapeutics was a new SageView Advisory Group position in Q4 2025.
  • Spero Therapeutics made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2572 holding.
  • 56 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.